Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to “Buy” at Maxim Group

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by Maxim Group from a “hold” rating to a “buy” rating in a research note issued on Thursday, MarketBeat Ratings reports. The firm presently has a $2.00 price target on the biotechnology company’s stock. Maxim Group’s price objective would indicate a potential upside of 376.19% from the stock’s current price.

Separately, StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics in a research note on Friday, July 5th. They issued a “hold” rating for the company.

Brainstorm Cell Therapeutics Stock Performance

BCLI stock opened at $0.42 on Thursday. The stock has a market cap of $29.43 million, a P/E ratio of -1.31 and a beta of 0.37. The firm has a 50 day simple moving average of $0.44 and a 200 day simple moving average of $0.42. Brainstorm Cell Therapeutics has a 52 week low of $0.13 and a 52 week high of $2.06.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. Sell-side analysts predict that Brainstorm Cell Therapeutics will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the stock is owned by hedge funds and other institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.